Atrial Natriuretic Peptide + Adrenomedullin Peptide Stack

This synergistic stack incorporates Atrial Natriuretic Peptide (ANP) and Adrenomedullin, both of which are pivotal in cardiovascular physiology. ANP is primarily involved in regulating blood volume and pressure, while Adrenomedullin has potent vasodilatory effects. Research suggests that the independent vasodilatory pathways of these peptides can be effectively measured in heart failure models, potentially offering insights into their combined therapeutic efficacy. The integration of these two peptides may facilitate a more comprehensive understanding of their roles in cardiovascular homeostasis and disease states, particularly in conditions characterized by volume overload or impaired vascular function.

Atrial Natriuretic Peptide (ANP) is a 28-amino-acid hormone secreted by atrial cardiomyocytes in response to increased atrial stretch caused by volume overload. This peptide is integral to the regulation of blood volume, sodium balance, and blood pressure. In Japan, a recombinant form known as carperitide is approved for acute heart failure, though it lacks approval in Western markets. Research indicates that ANP exerts its effects by binding to natriuretic peptide receptor A (NPR-A), leading to increased intracellular cGMP levels. This cascade activates protein kinase G (PKG), which results in the relaxation of vascular smooth muscle, enhanced glomerular filtration rate, and decreased sodium reabsorption. Additionally, ANP has been shown to inhibit sympathetic nervous system activity and suppress the release of renin and aldosterone. Its rapid clearance from circulation, primarily through NPR-C receptor-mediated internalization, results in a plasma half-life of approximately 2-5 minutes, underscoring its transient yet significant physiological role.

Adrenomedullin is a 52-amino-acid vasodilatory peptide originally identified in human pheochromocytoma tissue. It is expressed throughout the cardiovascular system, lungs, kidneys, and adrenal glands, where it exhibits vasodilatory, natriuretic, and cardioprotective properties. Current investigations focus on its potential as a biomarker (MR-proADM) for sepsis and heart failure prognosis, although the peptide itself has not yet received therapeutic approval. Adrenomedullin operates through the calcitonin receptor-like receptor (CLR) in conjunction with receptor activity-modifying proteins (RAMP2 or RAMP3), leading to the activation of Gs-coupled adenylyl cyclase. This process elevates cAMP levels, subsequently activating protein kinase A (PKA) and promoting endothelial nitric oxide synthase (eNOS) phosphorylation, resulting in nitric oxide release and vasodilation. Furthermore, Adrenomedullin enhances renal blood flow and inhibits aldosterone secretion, contributing to its natriuretic effects. The peptide is derived from a larger precursor, with a plasma half-life of approximately 22 minutes, while its more stable mid-regional fragment serves as a valuable biomarker in clinical settings.